Log in

NASDAQ:PGNXProgenics Pharmaceuticals Stock Price, Forecast & News

$4.24
-0.12 (-2.75 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.17
Now: $4.25
$4.40
50-Day Range
$3.41
MA: $3.91
$4.36
52-Week Range
$1.89
Now: $4.25
$6.37
Volume623,514 shs
Average Volume577,068 shs
Market Capitalization$367.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.
Read More
Progenics Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.99 million
Book Value$0.35 per share

Profitability

Net Income$-68,550,000.00
Net Margins-180.28%

Miscellaneous

Employees79
Market Cap$367.62 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

How has Progenics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Progenics Pharmaceuticals' stock was trading at $3.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PGNX stock has increased by 11.4% and is now trading at $4.2450. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Progenics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Progenics Pharmaceuticals.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Progenics Pharmaceuticals.

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) issued its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative return on equity of 129.46% and a negative net margin of 180.28%. View Progenics Pharmaceuticals' earnings history.

What price target have analysts set for PGNX?

3 analysts have issued 12-month price targets for Progenics Pharmaceuticals' shares. Their forecasts range from $10.00 to $14.00. On average, they expect Progenics Pharmaceuticals' share price to reach $12.00 in the next year. This suggests a possible upside of 182.7% from the stock's current price. View analysts' price targets for Progenics Pharmaceuticals.

Has Progenics Pharmaceuticals been receiving favorable news coverage?

Media coverage about PGNX stock has been trending somewhat negative on Saturday, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news aboutProgenics Pharmaceuticals.

Are investors shorting Progenics Pharmaceuticals?

Progenics Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 5,530,000 shares, a decline of 5.6% from the April 30th total of 5,860,000 shares. Based on an average daily volume of 965,800 shares, the short-interest ratio is currently 5.7 days. Approximately 7.1% of the shares of the stock are sold short. View Progenics Pharmaceuticals' Current Options Chain.

Who are some of Progenics Pharmaceuticals' key competitors?

What other stocks do shareholders of Progenics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), Opko Health (OPK), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX).

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the following people:
  • Mr. Mark R. Baker, CEO & Director (Age 64)
  • Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
  • Mr. Benedict Osorio, Chief Operating Officer (Age 62)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.99%), State Street Corp (5.35%), Geode Capital Management LLC (1.44%), Alliancebernstein L.P. (1.44%), Bank of New York Mellon Corp (1.07%) and Nuveen Asset Management LLC (1.06%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View institutional ownership trends for Progenics Pharmaceuticals.

Which institutional investors are selling Progenics Pharmaceuticals stock?

PGNX stock was sold by a variety of institutional investors in the last quarter, including CNH Partners LLC, BlackRock Inc., Wells Fargo & Company MN, Rafferty Asset Management LLC, Two Sigma Investments LP, Bank of New York Mellon Corp, UBS Group AG, and Arizona State Retirement System. View insider buying and selling activity for Progenics Pharmaceuticals.

Which institutional investors are buying Progenics Pharmaceuticals stock?

PGNX stock was acquired by a variety of institutional investors in the last quarter, including Yakira Capital Management Inc., Wolverine Asset Management LLC, Beryl Capital Management LLC, Alliancebernstein L.P., IndexIQ Advisors LLC, CSS LLC IL, Nuveen Asset Management LLC, and State Street Corp. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc, and Velan Capital, LP. View insider buying and selling activity for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.25.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $367.62 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.

What is Progenics Pharmaceuticals' official website?

The official website for Progenics Pharmaceuticals is www.progenics.com.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.